106 related articles for article (PubMed ID: 38743009)
1. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition.
O'Hare P; Cooney T; de Blank P; Gutmann DH; Kieran M; Milde T; Fangusaro J; Fisher M; Avula S; Packer R; Fukuoka K; Mankad K; Mueller S; Waanders AJ; Opocher E; Bouffet E; Raabe E; Werle NE; Azizi AA; Robison NJ; Hernáiz Driever P; Russo M; Schouten N; van Tilburg CM; Sehested A; Grill J; Bandopadhayay P; Kilday JP; Witt O; Ashley DM; Ertl-Wagner BB; Tabori U; Hargrave DR
Neuro Oncol; 2024 May; ():. PubMed ID: 38743009
[TBL] [Abstract][Full Text] [Related]
2. Pediatric low-grade glioma: State-of-the-art and ongoing challenges.
Fangusaro J; Jones DT; Packer RJ; Gutmann DH; Milde T; Witt O; Mueller S; Fisher MJ; Hansford JR; Tabori U; Hargrave D; Bandopadhayay P
Neuro Oncol; 2024 Jan; 26(1):25-37. PubMed ID: 37944912
[TBL] [Abstract][Full Text] [Related]
3. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNS; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O
BMC Cancer; 2024 Jan; 24(1):147. PubMed ID: 38291372
[TBL] [Abstract][Full Text] [Related]
4. Early experience with targeted therapy as a first-line adjuvant treatment for pediatric low-grade glioma.
Leclair NK; Lambert W; Roche K; Gillan E; Gell JJ; Lau CC; Wrubel G; Knopf J; Amin S; Anderson M; Martin JE; Bookland MJ; Hersh DS
Neurosurg Focus; 2022 Dec; 53(6):E15. PubMed ID: 36455272
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH
Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591
[TBL] [Abstract][Full Text] [Related]
6. Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
Mueller S; Fangusaro J; Thomas AO; Jacques TS; Bandopadhayay P; de Blank P; Packer RJ; Fouladi M; van Meeteren AS; Jones D; Perry A; Nakano Y; Hargrave D; Riedl D; Robison NJ; Partanen M; Fisher MJ; Witt O
Neuro Oncol; 2024 Mar; 26(3):407-416. PubMed ID: 38146999
[TBL] [Abstract][Full Text] [Related]
7. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
Sigaud R; Rösch L; Gatzweiler C; Benzel J; von Soosten L; Peterziel H; Selt F; Najafi S; Ayhan S; Gerloff XF; Hofmann N; Büdenbender I; Schmitt L; Foerster KI; Burhenne J; Haefeli WE; Korshunov A; Sahm F; van Tilburg CM; Jones DTW; Pfister SM; Knoerzer D; Kreider BL; Sauter M; Pajtler KW; Zuckermann M; Oehme I; Witt O; Milde T
Neuro Oncol; 2023 Mar; 25(3):566-579. PubMed ID: 35882450
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Pediatric Low-Grade Gliomas.
Sait SF; Giantini-Larsen AM; Tringale KR; Souweidane MM; Karajannis MA
Curr Neurol Neurosci Rep; 2023 Apr; 23(4):185-199. PubMed ID: 36881254
[TBL] [Abstract][Full Text] [Related]
9. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
11. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
12. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
13. Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.
Kocher D; Cao L; Guiho R; Langhammer M; Lai YL; Becker P; Hamdi H; Friedel D; Selt F; Vonhören D; Zaman J; Valinciute G; Herter S; Picard D; Rettenmeier J; Maass KK; Pajtler KW; Remke M; von Deimling A; Pusch S; Pfister SM; Oehme I; Jones DTW; Halbach S; Brummer T; Martinez-Barbera JP; Witt O; Milde T; Sigaud R
J Neurooncol; 2024 Jun; 168(2):317-332. PubMed ID: 38630384
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
[TBL] [Abstract][Full Text] [Related]
15. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era.
Manoharan N; Liu KX; Mueller S; Haas-Kogan DA; Bandopadhayay P
Neoplasia; 2023 Feb; 36():100857. PubMed ID: 36566593
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
17. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
[TBL] [Abstract][Full Text] [Related]
18. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.
Tsai JW; Choi JJ; Ouaalam H; Murillo EA; Yeo KK; Vogelzang J; Sousa C; Woods JK; Ligon KL; Warfield SK; Bandopadhayay P; Cooney TM
Neurooncol Adv; 2023; 5(1):vdac182. PubMed ID: 36926246
[TBL] [Abstract][Full Text] [Related]
19. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
20. Response and resistance to BRAF
Capogiri M; De Micheli AJ; Lassaletta A; Muñoz DP; Coppé JP; Mueller S; Guerreiro Stucklin AS
Front Oncol; 2022; 12():1074726. PubMed ID: 36698391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
